Over the past three months, Inovio Pharmaceuticals Inc. [INO] ended the trading day at $12.82 and exhibited a change of 3.14% with a 24 hour trading and reached upto the volume of 21.59M compared to its recorded trading volume of 8.92 million. INO generated a 1 year amount change with 501.88%. Though for Principal markets a year is counted as a long time period. By having a look at the most recent performance of this stock, in the last week its amount moved by 3.30% with an amount shift of 13.25% over the last month.

On 28, September 2020, INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800. According to news published on Yahoo Finance, INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company’s planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial. Until the FDA’s questions have been satisfactorily addressed, INOVIO’s Investigational New Drug Application (IND) for the Phase 2/3 trial is on partial clinical hold. The company is actively working to address the FDA’s questions and plans to respond in October, after which the FDA will have up to 30 days to notify INOVIO of its decision as to whether the trial may proceed.

Analyst Birdseye View:

The most recent analyst activity for Inovio Pharmaceuticals Inc. [NASDAQ:INO] stock was on September 28, 2020, when it was Downgrade with a Neutral rating from Cantor Fitzgerald. Before that, on September 28, 2020, Maxim Group Recapitulated a Buy rating and elevated its amount target to $20. On July 01, 2020, ROTH Capital Downgrade a Sell rating and boosted its price target on this stock to $11. On July 01, 2020, Maxim Group Downgrade a Hold rating. On June 29, 2020, H.C. Wainwright Downgrade a Neutral rating. On June 26, 2020, Stifel Downgrade a Hold rating and boosted its amount target on this stock to $24. On May 21, 2020, The Benchmark Company Initiated a Buy rating and boosted its target amount on this stock to $28. On April 30, 2020, ROTH Capital Downgrade a Neutral rating and amplified its amount target to $13.

In the past 52 weeks of trading, this stock has oscillated between a low of $2.09 and a peak of $33.79. Right now, according to Wall Street analyst the average 12-month amount target is $13.71. At the most recent market close, shares of Inovio Pharmaceuticals Inc. [NASDAQ:INO] were valued at $12.82. According to the average price forecast, investors can expect a potential return of -14.25%.

FUNDAMENTAL ANALYSIS

Inovio Pharmaceuticals Inc. [NASDAQ:INO] most recently reported quarterly sales of 267.2 million, which represented growth of 200.00%. This publicly-traded organization’s revenue is $21,196 per employee, while its income is -$615,254 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -84.31, -264.15, -122.34 and -127.11 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 96.66 and the whole liability to whole assets at 65.46. It shows enduring liability to the whole principal at 94.65 and enduring liability to assets at 0.64 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 12.46 points at 1st support level, the second support level is making up to 12.10. But as of 1st resistance point, this stock is sitting at 13.13 and at 13.44 for 2nd resistance point.

Inovio Pharmaceuticals Inc. [INO] reported its earnings at -$0.83 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.17/share signifying the difference of -0.66 and -388.20% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.26 calling estimates for -$0.22/share with the difference of -0.04 depicting the surprise of -18.20%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Inovio Pharmaceuticals Inc. [NASDAQ:INO] is 10.10. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.80. Now if looking for a valuation of this stock’s amount to sales ratio it’s 79.23 and it’s amount to book ratio is 97.37.

Insider Stories

The most recent insider trade was by Humeau Laurent, Chief Scientific Officer, and it was the sale of 19467.0 shares on Aug 10. Kim Jong Joseph, the Chief Executive Officer, completed a sale of 100000.0 shares on Jul 30. On Jul 15, KIES PETER, CFO, completed a sale of 35000.0 shares.